Reuters logo
BRIEF-Kempharm says granted "fast track" designation for KP201/IR
December 20, 2016 / 12:56 PM / 9 months ago

BRIEF-Kempharm says granted "fast track" designation for KP201/IR

Dec 20 (Reuters) - Kempharm Inc

* Remain on target for a potential submission in 2018 of KP201/IR NDA

* Investigational new drug application for KP201/IR granted “fast track” designation by U.S. Food and Drug Administration

* Expects to initiate human clinical trials of KP201/IR in first half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below